ClinomicsAI

Deep Proteomic Intelligence

Minimally invasive liquid biopsy proteomics + advanced bioinformatics — generating real-time molecular insights that inform precision medicine.

From liquid biopsy and proteome profiling through bioinformatic integration — surface drug-sensitive pathways, safety signals, and responder signatures with Stanford-licensed IP.

Capabilities

From molecular insight to precision strategy.

Leveraging minimally invasive liquid biopsy and high-resolution proteomic analytics, ClinomicsAI surfaces molecular pathway insights in real time — revealing on-target effects, off-target risks, and patient subpopulations most likely to respond to therapy.

  • Real-Time Molecular Insights

    Surface on-target and off-target molecular effects in real time — guiding development decisions while they still matter.

  • Drug-Sensitive Pathway Identification

    Identify which pathways respond to therapy and which don't — informing mechanistic refinement and indication strategy.

  • Efficacy Pathway Elucidation

    Surface the cellular and molecular pathways most relevant to your drug's mechanism of action — confirming on-target engagement.

  • Safety Pathway Identification

    Identify safety pathway perturbations early — informing dose, candidate selection, and regulatory dossier before risks materialize in late-stage trials.

  • Patient Response Prediction

    Predict which patients will respond to therapy based on their molecular signature — enabling biomarker-guided clinical enrollment.

  • Patient Population Selection & Stratification

    Stratify trial populations for precision enrichment and commercial targeting based on molecular phenotype.

Why ClinomicsAI

Minimally invasive. Maximally informative.

Traditional proteomics requires complex sample prep and large biological samples. ClinomicsAI uses a minimally invasive liquid biopsy approach — making longitudinal molecular monitoring practical for clinical trials and real-world studies.

Built on Stanford-licensed IP.

Translating cutting-edge proteomic and bioinformatic methods developed at Stanford University into platform-grade tools for biotech and pharma.

Stanford-Licensed IP

Minimally invasive sample collection.

Liquid biopsy makes longitudinal molecular monitoring practical across clinical trials and real-world studies — without complex sample prep.

Minimally Invasive Liquid Biopsy

Real-time molecular pathway insights.

Surface what's happening at the protein and pathway level in days, not months — guiding decisions while they still matter.

Real-Time Pathway Insights

On-target and off-target effects, surfaced.

Confirm target engagement and reveal off-target effects early — informing candidate selection, dose, and regulatory dossier.

On / Off-Target Effects

Discover drug-sensitive pathways.

Reveal which pathways respond to your therapy — and which don't — to inform mechanistic refinement and indication expansion.

Drug-Sensitive Pathway Discovery

Precision patient stratification & response prediction.

Identify which patients are most likely to respond — enabling biomarker-guided trial enrichment and targeted commercial strategy.

Patient Stratification

— Stanford IP · Licensed —

IP developed and licensed from Stanford University.

ClinomicsAI is built on intellectual property developed and licensed from Stanford University — translating cutting-edge proteomic and bioinformatic methods into platform-grade tools for biotech and pharma. The platform enables more informed therapeutic development and supports personalized treatment strategies.

Three Axes of Insight

Efficacy. Safety. Patient selection.

Efficacy

Pathway Elucidation

Surface the cellular and molecular pathways most relevant to your drug's mechanism — confirming on-target engagement and revealing how response is mediated at the protein level.

Safety

Off-Target & Risk Signal

Identify off-target effects and safety pathway perturbations early — informing dose, candidate selection, and regulatory dossier before risks materialize in late-stage trials.

Patient Selection

Stratification & Response

Predict which patients are most likely to respond — enabling precision trial enrichment, biomarker-guided patient selection, and targeted commercial strategy.

— Let's Work Together —

Ready to unlock the full strategic value of your science?

Tell us where you are in development and what you're trying to achieve. We'll follow up to explore how ClarezAI can help.

Start a Conversation See All Products